

VERTEX PHARMACEUTICALS INC / MA  
 Form 4  
 January 14, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**LEIDEN JEFFREY M**

2. Issuer Name and Ticker or Trading Symbol  
**VERTEX PHARMACEUTICALS INC / MA [VRTX]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
**C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE**

3. Date of Earliest Transaction (Month/Day/Year)  
**10/27/2015**

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**CEO & President**

(Street)  
**BOSTON, MA 02210**

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	8. Amount of Underlying Security (Instr. 3 and 4)
Stock Option (right to buy)	\$ 48.74	01/11/2016		G	88,500	<sup>(1)</sup> 07/24/2022	Common Stock	88,500
Stock Option (right to buy)	\$ 48.74	01/11/2016		G	88,500	<sup>(1)</sup> 07/24/2022	Common Stock	88,500
Stock Option (right to buy)	\$ 45.11	01/11/2016		G	110,625	<sup>(3)</sup> 02/04/2023	Common Stock	110,625
Stock Option (right to buy)	\$ 45.11	01/11/2016		G	110,625	<sup>(3)</sup> 02/04/2023	Common Stock	110,625

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210	X		CEO & President	

## Signatures

Omar White,  
Attorney-In-Fact

01/14/2016

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in 16 quarterly installments from 7/25/2012.

(2) Gift of options held by Dr. Leiden to a grantor retained annuity trust for the benefit of his immediate family members. Dr. Leiden maintains beneficial ownership over the shares subject to the options.

(3) The option vests in 16 quarterly installments from 2/5/2013.

## Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.